Anti-lipopolysaccharide immunotherapy in management of septic shock of obstetric and gynaecological origin.
Freeze-dried human plasma rich in anti-lipopolysaccharide (anti-LPS) immunoglobulin G was used to treat septic shock (systolic pressure less than or equal to 80 mm Hg, central venous pressure greater than or equal to 6 cm H2O) in obstetric and gynaecological patients. Mortality in conventionally treated patients was 9/19 (47.4%) compared with 1/14 (7.1%) in anti-LPS-treated patients. Anti-LPS caused the mean arterial pressure to rise from 45.1 +/- 7.36 mm Hg to 69.1 +/- 9.07 mm Hg within 75 min of administration. The mean hospital stay of survivors was 28.1 days for controls and 14.2 days for the anti-LPS-treated patients. The development of complications of septic shock was much reduced in the treated group. Anti-LPS thus appears significantly to reduce mortality and morbidity in septicaemia.
D000031:Abortion, Septic / Q000150:complications*; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D005831:Genital Diseases, Female / Q000150:complications*; D006801:Humans; D007116:Immunization, Passive; D007074:Immunoglobulin G / Q000276:immunology / Q000627:therapeutic use*; D007902:Length of Stay; D008070:Lipopolysaccharides / Q000276:immunology*; D011247:Pregnancy; D011897:Random Allocation; D012772:Shock, Septic / Q000209:etiology / Q000401:mortality / Q000628:therapy*
D007074:Immunoglobulin G; D008070:Lipopolysaccharides